On the stock market since 2021, it operates in the world of health and science. It has 115 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
The biggest line carries real weight, but it doesn’t decide everything on its own.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 14% a year on average.
Sales run at $26.6M a year. A small number, but proof the product has real buyers.
It met or beat analyst expectations in 7 of the last 7 quarters — consistency is a promise kept.
A loss of $91.8M against $26.6M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.0019. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, CELUW sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CELUW is a high-risk stock — not yet profitable, and its future rides on its product catching on.